However, retrospective studies of patients receiving anti-TNFα for immune-related diseases reported no reduction in the incidence of new onset NAFLD, NASH, or cirrhosis (423). This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.